Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06146257
Other study ID # GLB-001-01
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date January 11, 2024
Est. completion date October 8, 2026

Study information

Verified date February 2024
Source GluBio Therapeutics Inc.
Contact Hongying Zhang, MD
Phone 619-859-4586
Email Hongying.Zhang@glubiotx.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and expansion clinical study of GLB-001 in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). The dose escalation part (Phase 1a) of the study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-001 administered orally. Approximately 24 participants (up to 42 participants) may be enrolled in Phase 1a of the study. The dose expansion part (Phase 1b) will be followed to understand the relationships among dose, exposure, toxicity, tolerability and clinical activity, to identify minimally active dose, and to select the recommended dose(s) for phase 2 study. Up to 24 participants (12 participants per dose level) may be enrolled in Phase 1b of the study.


Description:

A standard 3+3 dose-escalation design will be applied to evaluate a set of several dose levels to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of GLB-001 in R/R AML or R/R HR-MDS patients who are eligible for DLT evaluation. The actual dose-escalation magnitude or dosing frequency may be adjusted based on the available PK and safety data in human. After the MTD or MAD of GLB-001 is defined in Phase 1a, 1 or 2 dose levels will be selected for expansion per safety review committee (SRC) recommendation, approximately 12 patients will be enrolled per dose level. Recommended phase 2 dose (RP2D) will be selected based on the results of PK, PD, safety and efficacy in the dose escalation and expansion study.


Recruitment information / eligibility

Status Recruiting
Enrollment 48
Est. completion date October 8, 2026
Est. primary completion date October 6, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participants is = 18 years of age at the time of signing the Informed Consent Form (ICF). - Participants must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted. - Participants are willing and able to adhere to the study visit schedule and other protocol requirements. - Participants with histologically or cytologically confirmed AML including de novo AML or secondary AML transformed from MDS according to 2022 World Health Organization (WHO) criteria classification, or with histologically or cytologically confirmed HR-MDS. - R/R AML and R/R HR-MDS who have failed or are ineligible for all available therapies which may provide clinical benefit. - Participants must have the following screening laboratory values: - Total white blood cell count (WBC) < 25 x 10^9/L prior to the first dose of the study drug. - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3.0 × upper limit of normal (ULN), unless considered due to extensive leukemic liver involvement, in which case AST and ALT can be = 5.0 x ULN. - Serum total bilirubin = 1.5 x ULN, unless considered due to Gilbert's syndrome, in which case serum total bilirubin < 3 x ULN. - Estimated serum creatinine clearance of = 60 mL/min using the Cockcroft-Gault equation. Measured creatinine clearance from a 24-hour urine collection is acceptable if clinically indicated. - International normalized ratio (INR) = 1.5 x ULN and active partial thromboplastin time (aPTT) = 1.5 x ULN. - Life expectancy = 12 weeks. - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2. - Female Participants of child-bearing potential must have a negative serum or urine pregnancy test at screening and at pre-dose on Cycle 1 Day 1 (C1D1). Exclusion Criteria: - Participants with acute promyelocytic leukemia (APML). - Participants with known leukemic involvement in central nervous system (CNS). - Receipt of anticancer medications/therapies within 5 half-lives or 28 days before the first administration of the study drug. - Participants with unresolved clinically significant non-hematologic toxicities of = Grade 2 AE from prior therapies with exception of residual alopecia. - Participants with chronic graft versus host disease (GVHD) requiring systemic immunosuppressive therapy. - Participants with active malignancies other than AML or MDS. - Participants who have undergone major surgery = 4 weeks prior to the first dose of the study drug. - Participants with immediately life-threatening, severe complications of leukemia such as disseminated/uncontrolled infection (bacterial and/or fungal), uncontrolled bleeding, and/or uncontrolled disseminated intravascular coagulation. - Participants with known chronic, active infection of hepatitis B virus (HBV), hepatitis C virus C (HCV), human immunodeficiency virus (HIV). - Participants unable to swallow oral medications, or Participants with clinically significant diarrhea, vomiting or malabsorption felt limited absorption of orally administered medications. - Participants with any other significant medical conditions, any other conditions, laboratory abnormality, or psychiatric illness which place the Participants at unacceptable risk if he/she were to participate in the study or that would hamper the Participants understanding of the study, or would prevent the Participant from complying with the study. - Medications or supplements that are known to be strong and moderate inhibitors or inducers of CYP450 isozyme 3A4 (CYP3A4) and/or P-glycoprotein (P-gp), or strong inhibitors or inducers of CYP450 isozyme 2C8 (CYP2C8) within 14 days or 5 half-lives, whichever is shorter, before the first dose of study drug. - Pregnant or lactating women.

Study Design


Intervention

Drug:
GLB-001
Administered orally according to the assigned treatment schedule

Locations

Country Name City State
United States Roswell Park Comprehensive Cancer Center Buffalo New York
United States City of Hope Medical Center Duarte California
United States University of Texas M. D. Anderson Cancer Center Houston Texas
United States University of California Irvine Irvine California
United States University of Kansas Medical Center Research Institute, Inc. Kansas City Kansas
United States Alliance for Multispecialty Research, LLC Merriam Kansas
United States Icahn School of Medicine at Mount Sinai New York New York
United States Memorial Sloan Kettering Cancer Center-David H. Koch Center New York New York

Sponsors (1)

Lead Sponsor Collaborator
GluBio Therapeutics Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-limiting Toxicity (DLT) Dose-limiting toxicity is defined as the treatment emergent adverse events (TEAEs) meeting protocol specified DLT criteria and occurring within the DLT assessment period. Up to 28 days after first dose of study treatment in Phase 1a
Primary Maximum Tolerated Dose (MTD)/Maximum Administered Dose (MAD) Maximum tolerated dose is defined as the highest dose level at which no more than 1 of 6 DLT-evaluable participants experienced a DLT. If MTD is not established at the end of dose escalation phase, the maximum safety dose will be defined as Maximum administered dose. Up to 2 years
Primary Incidence of Adverse Events (AEs) Adverse Events will be graded according to the National Cancer Institute Common Terminology Criteria for AE (NCI CTCAE) version 5.0. Up to 2 years
Primary Recommended Phase 2 Dose (RP2D) Recommended phase 2 dose based on the totality of data across dosing cohorts in the dose escalation and expansion phases of the study including PK, PD, safety and efficacy outcomes. Up to 2 years
Secondary GLB-001 Pharmacokinetics-AUC0-last Area under the concentration-time curve from zero to the last measurable concentration. Up to 2 years
Secondary GLB-001 Pharmacokinetics-AUC0-24 Area under the concentration-time curve from 0 to 24 hours. Up to 2 years
Secondary GLB-001 Pharmacokinetics-AUC0-8 Area under the concentration-time curve from 0 to infinity. Up to 2 years
Secondary GLB-001 Pharmacokinetics-Cmax Maximum plasma concentration. Up to 2 years
Secondary GLB-001 Pharmacokinetics-Tmax The time to reach maximum concentration. Up to 2 years
Secondary GLB-001 Pharmacokinetics-T1/2 Terminal half-life. Up to 2 years
Secondary GLB-001 Pharmacokinetics-Vd/F Apparent volume of distribution. Up to 2 years
Secondary GLB-001 Pharmacokinetics-LI Linear index. Up to 2 years
Secondary GLB-001 Pharmacokinetics-CL/F Apparent clearance. Up to 2 years
Secondary GLB-C183-A-2R (Isomer of GLB-001) Pharmacokinetics-AUC0-last Area under the concentration-time curve from zero to the last measurable concentration. Up to 2 years
Secondary GLB-C183-A-2R Pharmacokinetics-AUC0-24 Area under the concentration-time curve from 0 to 24 hours. Up to 2 years
Secondary GLB-C183-A-2R Pharmacokinetics-AUC0-8 Area under the concentration-time curve from 0 to infinity. Up to 2 years
Secondary GLB-C183-A-2R Pharmacokinetics-Cmax Maximum plasma concentration. Up to 2 years
Secondary GLB-C183-A-2R Pharmacokinetics-Tmax The time to reach maximum concentration. Up to 2 years
Secondary GLB-C183-A-2R Pharmacokinetics-T1/2 Terminal half-life. Up to 2 years
Secondary GLB-C183-A-2R Pharmacokinetics-Vd/F Apparent volume of distribution. Up to 2 years
Secondary GLB-C183-A-2R Pharmacokinetics-LI Linear index. Up to 2 years
Secondary GLB-C183-A-2R Pharmacokinetics-CL/F Apparent clearance. Up to 2 years
Secondary Complete Remission Without Minimal Residual Disease (CRMRD-) Rate in Participants with Acute Myeloid Leukemia (AML) CRMRD- rate is defined as the percent of participants with minimal residual disease negative complete remission. CRMRD- will be assessed by the 2022 European Leukemia Net Response Criteria (2022 ELN) for AML . Up to 2 years
Secondary Complete Remission (CR) Rate in Participants with AML CR rate is defined as the percent of participants whose best response is CR. CR will be assessed by 2022 ELN for AML. Up to 2 years
Secondary CR with Incomplete Hematologic Recovery (CRi) Rate in Participants with AML CRi rate is defined as the percent of participants whose best response is CRi. CRi will be assessed by 2022 ELN for AML. Up to 2 years
Secondary CR with Partial Hematological Recovery (CRh) Rate in Participants with AML CRh rate is defined as the percent of participants whose best response is CRh. CRh will be assessed by 2022 ELN for AML. Up to 2 years
Secondary Morphologic Leukemia-free State (MLFS) Rate in Participants with AML MLFS rate is defined as the percent of participants with the best response of morphologic leukemia-free state. MLFS will be assessed by 2022 ELN for AML. Up to 2 years
Secondary Partial Remission (PR) Rate in Participants with AML PR rate is defined as the percent of participants whose best response is PR. PR will be assessed by 2022 ELN for AML. Up to 2 years
Secondary Duration of Remission or Response (DOR) in Participants with AML For participants with best response of any of CRMRD-, CR, CRh, CRi, PR, and MLFS, DOR is measured from the time when criteria (2022 ELN for AML) for the best response of any of CRMRD-, CR, CRh, CRi, PR, and MLFS are first met (whichever is first recorded) until the first date at which relapse, or progressive disease is objectively documented assessment. Up to 2 years
Secondary Time to Remission or Response (TOR) in Participants with AML Time to onset of first remission or response is defined as the time interval from the date of first dose and the earliest date any remission or response [any CRs (including CR, CRh and CRi) or PR] is observed. Up to 2 years
Secondary Stable Disease (SD) Rate in Participants with AML SD rate is defined as the percent of participants with the best response of stable disease. SD will be assessed by 2022 ELN for AML. Up to 2 years
Secondary CR Rate in Participants with Higher Risk Myelodysplastic Syndromes (HR-MDS) CR rate is defined as the percent of participants whose best response is CR. CR will be assessed by 2006 Modified International Working Group (IWG) MDS response criteria. Up to 2 years
Secondary PR Rate in Participants with HR-MDS PR rate is defined as the percent of participants whose best response is PR. PR will be assessed by 2006 Modified IWG MDS response criteria. Up to 2 years
Secondary SD Rate in Participants with HR-MDS SD rate is defined as the percent of participants with the best response of stable disease. SD will be assessed by 2006 Modified IWG MDS response criteria. Up to 2 years
Secondary DOR in Participants with HR-MDS For participants with best response of any of CR, marrow CR, or PR, DOR is measured from the time when criteria (2006 Modified IWG MDS response criteria) for the best response of any of CR, marrow CR, or PR are first met (whichever is first recorded) until the first date at which relapse or progressive disease is objectively documented assessment. Up to 2 years
Secondary TOR in Participants with HR-MDS Time to onset of first remission or response is defined as the time interval from the date of first dose of GLB-001 and the earliest date any remission or response [any CRs (including CR, marrow CR or PR)] is observed. Up to 2 years
Secondary Progression-free Survival (PFS) in Participants with AML or HR-MDS PFS is defined as the time from the first dose of GLB-001 to the first occurrence of relapse or progression or death from any cause. Up to 2 years
Secondary Overall Survival (OS) in Participants with AML or HR-MDS OS is defined as the time from the first dose of GLB-001 to death due to any cause. Up to 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Completed NCT04022785 - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Completed NCT03678493 - A Study of FMT in Patients With AML Allo HSCT in Recipients Phase 2
Recruiting NCT05424562 - A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
Completed NCT03197714 - Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia Phase 1
Terminated NCT03224819 - Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) Early Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT04070768 - Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 Phase 1
Active, not recruiting NCT04107727 - Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT04385290 - Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) Phase 1/Phase 2
Recruiting NCT04920500 - Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients N/A
Recruiting NCT03897127 - Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics Phase 3
Active, not recruiting NCT04021368 - RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Phase 1
Recruiting NCT03665480 - The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML Phase 2/Phase 3
Completed NCT02485535 - Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Phase 1
Enrolling by invitation NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Phase 2
Recruiting NCT04069208 - IA14 Induction in Young Acute Myeloid Leukemia Phase 2
Recruiting NCT05744739 - Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 1
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2